- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | SAB Biotherapeutics reports Q1 results | 2 | Seeking Alpha | ||
| 09.05. | SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates | 190 | GlobeNewswire (Europe) | MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 09.05. | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.04. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 01.04. | SAB Biotherapeutics stock holds $6 target with Buy rating | 2 | Investing.com | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | SAB Biotherapeutics reports FY results | 3 | Seeking Alpha | ||
| 31.03. | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results | 255 | GlobeNewswire (Europe) | MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 05.02. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.01. | Why Is SAB BIO Stock Trading Lower On Tuesday? | 6 | Benzinga.com | ||
| 28.01. | Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings | 689 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59.
Planet... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 | 404 | GlobeNewswire (Europe) | SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy | 4 | GlobeNewswire (USA) | ||
| 06.01. | Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 | 1 | Insider Monkey | ||
| 06.11.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | 185 | GlobeNewswire (Europe) | Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov.... ► Artikel lesen | |
| 08.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 252 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
| 05.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 575 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
| 31.07.24 | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 183 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
| 20.06.24 | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 233 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.05.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer | 276 | GlobeNewswire (Europe) | MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,80 | +0,36 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| CUREVAC | 3,094 | +0,72 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| AMGEN | 243,10 | +0,10 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| NOVAVAX | 5,607 | -0,55 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| BIOGEN | 109,30 | -1,18 % | Goldman Sachs maintains Biogen buy rating, $196 target | ||
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - F-1/A, Registration statement for certain foreign private issuers | ||
| VIKING THERAPEUTICS | 24,430 | -0,33 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,148 | -1,00 % | Guggenheim cuts Intellia stock price target to $45, maintains buy | ||
| BIOCRYST PHARMACEUTICALS | 9,078 | -0,53 % | FDA awards BioCryst's Orladeyo NDA for paediatric HAE | ||
| SAREPTA THERAPEUTICS | 31,660 | +0,48 % | Sarepta Therapeutics' Elevidys Gets Approval In Japan To Treat Duchenne Muscular Dystrophy | WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,950 | -6,50 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,940 | -1,28 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| EXELIXIS | 41,800 | +1,02 % | Demystifying Exelixis: Insights From 8 Analyst Reviews | ||
| VAXART | 0,369 | -2,54 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen | |
| TEMPUS AI | 62,60 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,940 Euro und damit -3,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.